Table 5.

Risk differences between high and low glucocorticoid exposure (compared with glucocorticoid exposure in the GiACTA study) of any SAE over 52 weeks by study cohort

Exposure type	Risk difference by cutoff for high vs. low GC exposure (95% CI)a
	US cohort (N = 4804)	UK cohort (N = 3973)
Cutoff based on mean cumulative GC exposure in patients who received tocilizumab weekly (%)	9.25 (4.73, 13.77)b	6.05 (1.67, 10.43)b
Cutoff based on mean cumulative GC exposure in patients who received tocilizumab every other week (%)	9.22 (4.73, 13.72)b	6.19 (2.11, 10.27)b

GC glucocorticoid, SAE serious adverse event

^aHigh GC exposure: cumulative GC dose > mean cumulative GC dose in patients who received tocilizumab in the GiACTA study. Low GC exposure: cumulative GC dose ≤ mean cumulative GC dose in patients who received tocilizumab in the GiACTA study. Regression adjusted for covariates of age, sex, Charlson Comorbidity Index, and previous disease history

^bP < 0.05